Blood vessel formation in the tissue-engineered bone with the constitutively active form of HIF-1α mediated BMSCs

Biomaterials

Volumn 33, Issue 7, 2012, Pages 2097-2108

  Zou, Duohong ^a,b,c   Zhang, Zhiyuan ^b   He, Jiacai ^c   Zhang, Kai ^d   Ye, Dongxia ^b   Han, Wei ^e   Zhou, Jian ^c   Wang, Yuanyin ^c   Li, Quanli ^c   Liu, Xin ^c   Zhang, Xin ^a   Wang, Shaoyi ^b   Hu, Jingzhou ^b   Zhu, Chao ^b   Zhang, Wenjie ^b   zhou, Yong ^b   Fu, Honghai ^b   Huang, Yuanliang ^a   Jiang, Xinquan ^b  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d BENGBU MEDICAL COLLEGE   (China)

^e Jiangsu Province Engineering Research Center of Stomatological Translational Medicine   (China)

Author keywords

Angiogenesis; Gene therapy; HIF 1a; The tissue engineered bone

Indexed keywords

ANGIOGENESIS; ANGIOGENIC FACTOR; ANGIOPOIETINS; BASIC FIBROBLAST GROWTH FACTOR; BONE DEFECT; CALVARIAL DEFECTS; CLINICAL OUTCOME; CONSTITUTIVELY ACTIVES; CONTROL GROUPS; GELATIN SPONGE; GROWTH FACTOR; HIF-1A; HYPOXIA-INDUCIBLE FACTOR 1; IN-VITRO; IN-VIVO; MESENCHYMAL STEM CELL; MICRO CT; OVER-EXPRESSION; STEM CELL FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR NETWORK; VASCULAR REMODELING; VASCULARIZATION; VESSEL FORMATION;

BIOMATERIALS; BLOOD; BLOOD VESSELS; BONE; CELL CULTURE; COMPUTERIZED TOMOGRAPHY; DEFECTS; ENDOTHELIAL CELLS; GENE THERAPY; GENES; PEPTIDES; PHOTOMASKS; STEM CELLS; TISSUE;

TISSUE ENGINEERING;

ANGIOPOIETIN 1; FIBROBLAST GROWTH FACTOR 2; GELATIN SPONGE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENTIVIRUS VECTOR; MESSENGER RNA; PLACENTAL GROWTH FACTOR; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE REMODELING; CALVARIA; CONTROLLED STUDY; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHOTOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SKULL DEFECT; TISSUE ENGINEERING; VASCULARIZATION;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE MARROW CELLS; CELL ADHESION; CELLS, CULTURED; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MESENCHYMAL STEM CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, INBRED F344; TISSUE ENGINEERING; TRANSDUCTION, GENETIC; X-RAY MICROTOMOGRAPHY;

LENTIVIRUS; RATTUS;

EID: 84855750276     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.11.053     Document Type: Article

References (44)

1. Oreffo R.O., Triffitt J.T. Future potentials for using osteogenic stem cells and biomaterials in orthopedics. Bone 1999, 25(2 suppl.):5S-9S.
2. Bauer T.W., Muschler G.F. Bone graft materials. An overview of the basic science. Clin Orthop Relat Res 2000, 371:10-27.
3. Yu H., VandeVord P.J., Mao L., Matthew H.W., Wooley P.H., Yang S.Y. Improved tissue-engineered bone regeneration by endothelial cell mediated vascularization. Biomaterials 2009, 30(4):508-517.
4. Santos M.I., Reis R.L. Vascularization in bone tissue engineering: physiology, current strategies, major hurdles and future challenges. Macromol Biosci 2010, 10(1):12-27.
5. Haller A. Experimentorum de ossiem formatione 1763, vol. 2. p. 400, Francisci Grasset.
6. Hunter J. Treatise on the blood, inflammation and gunshot wounds 1794, [London]. G. Nicol (Ed.).
7. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9(6):653-660.
8. Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 2005, 90(3):315-326.
9. Riddle R.C., Khatri R., Schipani E., Clemens T.L. Role of hypoxia-inducible factor-1alpha in angiogenic-osteogenic coupling. JMol Med (Berl) 2009, 87(6):583-590.
10. Xiao C., Zhou H., Liu G., Zhang P., Fu Y., Gu P., et al. Bone marrow stromal cells with a combined expression of BMP-2 and VEGF-165 enhanced bone regeneration. Biomed Mater 2011, 6(1):015013.
11. Qu D., Li J., Li Y., Gao Y., Zuo Y., Hsu Y., et al. Angiogenesis and osteogenesis enhanced by bFGF exvivo gene therapy for bone tissue engineering in reconstruction of calvarial defects. JBiomed Mater Res A 2011, 96(3):543-551.
12. Bohnsack B.L., Hirschi K.K. The FAKs about blood vessel assembly. Circ Res 2003, 92(3):255-257.
13. Cenni E., Perut F., Baldini N. Invitro models for the evaluation of angiogenic potential in bone engineering. Acta Pharmacol Sin 2011, 32(1):21-30.
14. Carmeliet P.V.E.G.F. gene therapy: stimulating angiogenesis or angioma- genesis. Nat Med 2000, 6(10):1102-1103.
15. Thurston G., Rudge J.S., Ioffe E., Zhou H., Ross L., Croll S.D., et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000, 6(4):460-463.
16. Mole D.R., Blancher C., Copley R.R., Pollard P.J., Gleadle J.M., Ragoussis J., et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. JBiol Chem 2009, 284(25):16767-16775.
17. Xia X., Lemieux M.E., Li W., Carroll J.S., Brown M., Liu X.S., et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A 2009, 106(11):4260-4265.
18. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003, 22(16):4082-4090.
19. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9(6):677-684.
20. Pugh C.W., O'Rourke J.F., Nagao M., Gleadle J.M., Ratcliffe P.J. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. JBiol Chem 1997, 272(17):11205-11214.
21. Mahon P.C., Hirota K., Semenza G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001, 15(20):2675-2686.
22. Zou D., Zhang Z., He J., Zhu S., Wang S., Zhang W., et al. Repairing critical-sized calvarial defects with BMSCs modified by a constitutively active form of hypoxia-inducible factor-1alpha and a phosphate cement scaffold. Biomaterials 2011, 32(36):9707-9718.
23. Zou D., Zhang Z., Ye D., Tang A., Deng L., Han W., et al. Repair of critical-sized rat calvarial defects using genetically engineered bone marrow-derived mesenchymal stem cells overexpressing hypoxia-inducible factor-1alpha. Stem Cells 2011, 29(9):1380-1390.
24. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408.
25. Bolland B.J., Kanczler J.M., Dunlop D.G., Oreffo R.O. Development of invivo muCT evaluation of neovascularisation in tissue engineered bone constructs. Bone 2008, 43(1):195-202.
26. Kelly B.D., Hackett S.F., Hirota K., Oshima Y., Cai Z., Berg-Dixon S., et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003, 93(11):1074-1081.
27. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10(8):858-864.
28. Manalo D.J., Rowan A., Lavoie T., Natarajan L., Kelly B.D., Ye S.Q., et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005, 105(2):659-669.
29. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9(6):669-676.
30. Carr A.N., Howard B.W., Yang H.T., Eby-Wilkens E., Loos P., Varbanov A., et al. Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: support for an endothelium-dependent mechanism. Cardiovasc Res 2006, 69(4):925-935.
31. Tomanek R.J., Lotun K., Clark E.B., Suvarna P.R., Hu N. VEGF and bFGF stimulate myocardial vascularization in embryonic chick. Am J Physiol 1998, 274(5 Pt 2):H1620-H1626.
32. Fukuhara S., Sako K., Noda K., Zhang J., Minami M., Mochizuki N. Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis. Histol Histopathol 2010, 25(3):387-396.
33. Ziche M., Maglione D., Ribatti D., Morbidelli L., Lago C.T., Battisti M., et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 1997, 76(4):517-531.
34. Duarte R.F., Frank D.A. SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways. Blood 2000, 96(10):3422-3430.
35. Rohanizadeh R., Swain M.V., Mason R.S. Gelatin sponges (Gelfoam) as a scaffold for osteoblasts. JMater Sci Mater Med 2008, 19(3):1173-1182.
36. Ponticiello M.S., Schinagl R.M., Kadiyala S., Barry F.P. Gelatin-based resorbable sponge as a carrier matrix for human mesenchymal stem cells in cartilage regeneration therapy. JBiomed Mater Res 2000, 52(2):246-255.
37. Bodner L. Effect of decalcified freeze-dried bone allograft on the healing of jaw defects after cyst enucleation. JOral Maxillofac Surg 1996, 54(11):1282-1286.
38. Zelzer E., Olsen B.R. Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. Curr Top Dev Biol 2005, 65:169-187.
39. Wang Y., Wan C., Gilbert S.R., Clemens T.L. Oxygen sensing and osteogenesis. Ann N Y Acad Sci 2007, 1117:1-11.
40. Street J., Bao M., deGuzman L., Bunting S., Peale F.V., Ferrara N., et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 2002, 99(15):9656-9661.
41. Dai J., Rabie A.B. VEGF: an essential mediator of both angiogenesis and endochondral ossification. JDent Res 2007, 86(10):937-950.
42. Sarkar K., Fox-Talbot K., Steenbergen C., Bosch-Marce M., Semenza G.L. Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice. Proc Natl Acad Sci U S A 2009, 106(44):18769-18774.
43. Rey S., Lee K., Wang C.J., Gupta K., Chen S., McMillan A., et al. Synergistic effect of HIF-1alpha gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia. Proc Natl Acad Sci U S A 2009, 106(48):20399-20404.
44. Bosch-Marce M., Okuyama H., Wesley J.B., Sarkar K., Kimura H., Liu Y.V., et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res 2007, 101(12):1310-1318.